Abstract
The field of transplantation has provided tremendous progress to diabetic patients. One way to objectify this development is to determine the survival benefit of transplantation in the four diabetic recipient categories: simultaneous pancreas/kidney transplant (SPK), pancreas after kidney transplant (PAK), pancreas transplant alone (PTA), and kidney transplant alone (KTA). Over a 21-year time period, from January 1, 2000, to May 31, 2021, the International Pancreas Transplant Registry/United Network for Organ Sharing (IPTR/UNOS) collected information about listing and transplant outcome of diabetic patients. A total of 212,049 patient records were reviewed: 89,579 recipients who underwent pancreas and/or kidney transplantation and 122,470 patients who were placed on the waiting list and are still waiting or were removed from the waitlist due to deteriorating health or death. To determine the survival benefit of pancreas transplantation, patient survival on the waiting list versus after transplantation was defined as primary outcome. Over the 21-year time period, pancreas and/or kidney transplantation in all 4 diabetic recipient categories saved a total of 273,843 life-years. On average, 11.7 life-years per patient were saved in the SPK category, 6.4 life-years in the PTA category, 6.3 life-years in the PAK category, and 6.6 life-years in the KTA category. The survival benefit of pancreas and/or kidney transplant recipients was highly significant compared to diabetic patients still waiting for transplantation. The survival benefit was higher for patients with type 1 versus type 2 diabetes mellitus. The significant survival benefit of PTA recipients versus patients on the waiting list justifies the argument for pre-emptive pancreas transplantation, i.e., before the development of end-stage renal disease. Given the survival benefit as evidenced in 273,843 life-years saved, pancreas transplantation should be more widely applied, and pancreas donation encouraged.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Port FK, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270(11):1339–43.
Merion RM, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA. 2005;294(21):2726–33.
Ojo AO, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001;12(3):589–97.
Merion RM, et al. The survival benefit of liver transplantation. Am J Transplant. 2005;5(2):307–13.
Schnitzler MA, et al. The life-years saved by a deceased organ donor. Am J Transplant. 2005;5(9):2289–96.
Rana A, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252–9.
Meier-Kriesche HU, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12(6):1293–6.
Terasaki PI, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333(6):333–6.
Ojo AO, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation. 2001;71(1):82–90.
White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet. 2009;373(9677):1808–17.
Rayhill SC, et al. Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival? Ann Surg. 2000;231(3):417–23.
Smets YF, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet. 1999;353(9168):1915–9.
Esmeijer K, et al. Superior long-term survival for simultaneous pancreas-kidney transplantation as renal replacement therapy: 30-year follow-up of a Nationwide cohort. Diabetes Care. 2020;43(2):321–8.
Venstrom JM, et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003;290(21):2817–23.
Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant. 2004;4(12):2018–26.
van Dellen D, et al. Mortality in diabetes: pancreas transplantation is associated with significant survival benefit. Nephrol Dial Transplant. 2013;28(5):1315–22.
Gruessner S, et al. Employment pattern after pancreas transplantation - facts and risk factors - a registry analysis. Rev Diabet Stud. 2017; 14(1).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gruessner, R.W.G., Gruessner, A.C. (2023). Survival Benefit of Pancreas Transplantation. In: Gruessner, R.W.G., Gruessner, A.C. (eds) Transplantation of the Pancreas. Springer, Cham. https://doi.org/10.1007/978-3-031-20999-4_67
Download citation
DOI: https://doi.org/10.1007/978-3-031-20999-4_67
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-20998-7
Online ISBN: 978-3-031-20999-4
eBook Packages: MedicineMedicine (R0)